Chick chorioallantoic membrane (CAM) assay for the evaluation
of the antitumor and antimetastatic activity of platinum-based
drugs in association with the impact on the amino acid
metabolism

J 2023

Chick chorioallantoic membrane (CAM) assay for the evaluation of the antitumor and antimetastatic activity of platinum-based drugs in association with the impact on the amino acid metabolism

MITREVSKA, Katerina, Miguel Angel Merlos RODRIGO, Natalia CERNEI, Hana MICHALKOVA, Zbynek SPLICHAL et. al.

Basic information

Original name

Chick chorioallantoic membrane (CAM) assay for the evaluation of the antitumor and antimetastatic activity of platinum-based drugs in association with the impact on the amino acid metabolism

Authors

Edition

Materials Today Bio, AMSTERDAM, Elsevier, 2023, 2590-0064

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

20601 Medical engineering

Country of publisher

Netherlands

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

URL

Impact factor

Impact factor: 8.200 in 2022

RIV identification code

RIV/00216224:90242/23:00133762

DOI

http://dx.doi.org/10.1016/j.mtbio.2023.100570

UT WoS

000931958900001

Keywords in English

Platinum nanoparticles; Cisplatin; CAM assay; Breast cancer; Amino acids metabolism; TCA cycle

Abstract

V originále

The combination of in ovo and ex ovo chorioallantoic membrane (CAM) assay provides an excellent platform which extends its relevance in studying carcinogenesis to the field of screening of anticancer activity of platinum nanoparticles (PtNPs) and further study of the amino acids' fluctuations in liver and brain. PtNPs are promising candidates for replacing cisplatin (CDDP); however, insufficient data of their antitumor efficiency and activity on the cancer-related amino acid metabolism are available, and the assessment of the in vivo performance has barely scratched the surface. Herein, we used CAM assay as in vivo model for screening of novel therapeutic modalities, and we conducted a comparative study of the effects of CDDP and polyvinylpyrrolidone coated PtNPs on MDA-MB-231 breast cancer xenograft. PtNPs showed a higher efficiency to inhibit the tumor growth and metastasis compared to CDDP. The amino acids profiling in the MDA-MB-231 cells revealed that the PtNPs had an overall depleting effect on the amino acids content. Noteworthy, more side effects to amino acid metabolism were deduced from the depletion of the amino acids in tumor, brain, and liver upon CDDP treatment. Different sets of enzymes of the tricarboxylic acid (TCA) cycle were targeted by PtNPs and CDDP, and while mRNA encoding multiple enzymes was downregulated by PtNPs, the treatment with CDDP affected only two TCA enzymes, indicating a different mechanism of action. Taken together, CAM assay represents and invaluable model, demonstrating the PtNPs capability of repressing angiogenesis, decrease amino acid contents and disrupt the TCA cycle.

Links

90242, large research infrastructures

Name: CIISB III

Citovat

MITREVSKA, Katerina, Miguel Angel Merlos RODRIGO, Natalia CERNEI, Hana MICHALKOVA, Zbynek SPLICHAL, David HYNEK, Ondrej ZITKA, Zbynek HEGER, Pavel KOPEL, Vojtech ADAM and Vedran MILOSAVLJEVIC. Chick chorioallantoic membrane (CAM) assay for the evaluation of the antitumor and antimetastatic activity of platinum-based drugs in association with the impact on the amino acid metabolism. Materials Today Bio. AMSTERDAM: Elsevier, 2023, vol. 19, Apr, p. 1-14. ISSN 2590-0064. Available from: https://dx.doi.org/10.1016/j.mtbio.2023.100570.

@article{2383577,
   author = {Mitrevska, Katerina and Rodrigo, Miguel Angel Merlos and Cernei, Natalia and Michalkova, Hana and Splichal, Zbynek and Hynek, David and Zitka, Ondrej and Heger, Zbynek and Kopel, Pavel and Adam, Vojtech and Milosavljevic, Vedran},
   article_location = {AMSTERDAM},
   article_number = {Apr},
   doi = {http://dx.doi.org/10.1016/j.mtbio.2023.100570},
   keywords = {Platinum nanoparticles; Cisplatin; CAM assay; Breast cancer; Amino acids metabolism; TCA cycle},
   language = {eng},
   issn = {2590-0064},
   journal = {Materials Today Bio},
   title = {Chick chorioallantoic membrane (CAM) assay for the evaluation of the antitumor and antimetastatic activity of platinum-based drugs in association with the impact on the amino acid metabolism},
   url = {https://www.sciencedirect.com/science/article/pii/S2590006423000303?via%3Dihub},
   volume = {19},
   year = {2023}
}

TY  - JOUR
ID  - 2383577
AU  - Mitrevska, Katerina - Rodrigo, Miguel Angel Merlos - Cernei, Natalia - Michalkova, Hana - Splichal, Zbynek - Hynek, David - Zitka, Ondrej - Heger, Zbynek - Kopel, Pavel - Adam, Vojtech - Milosavljevic, Vedran
PY  - 2023
TI  - Chick chorioallantoic membrane (CAM) assay for the evaluation of the antitumor and antimetastatic activity of platinum-based drugs in association with the impact on the amino acid metabolism
JF  - Materials Today Bio
VL  - 19
IS  - Apr
SP  - 1-14
EP  - 1-14
PB  - Elsevier
SN  - 25900064
KW  - Platinum nanoparticles
KW  - Cisplatin
KW  - CAM assay
KW  - Breast cancer
KW  - Amino acids metabolism
KW  - TCA cycle
UR  - https://www.sciencedirect.com/science/article/pii/S2590006423000303?via%3Dihub
N2  - The combination of in ovo and ex ovo chorioallantoic membrane (CAM) assay provides an excellent platform which extends its relevance in studying carcinogenesis to the field of screening of anticancer activity of platinum nanoparticles (PtNPs) and further study of the amino acids' fluctuations in liver and brain. PtNPs are promising candidates for replacing cisplatin (CDDP); however, insufficient data of their antitumor efficiency and activity on the cancer-related amino acid metabolism are available, and the assessment of the in vivo performance has barely scratched the surface. Herein, we used CAM assay as in vivo model for screening of novel therapeutic modalities, and we conducted a comparative study of the effects of CDDP and polyvinylpyrrolidone coated PtNPs on MDA-MB-231 breast cancer xenograft. PtNPs showed a higher efficiency to inhibit the tumor growth and metastasis compared to CDDP. The amino acids profiling in the MDA-MB-231 cells revealed that the PtNPs had an overall depleting effect on the amino acids content. Noteworthy, more side effects to amino acid metabolism were deduced from the depletion of the amino acids in tumor, brain, and liver upon CDDP treatment. Different sets of enzymes of the tricarboxylic acid (TCA) cycle were targeted by PtNPs and CDDP, and while mRNA encoding multiple enzymes was downregulated by PtNPs, the treatment with CDDP affected only two TCA enzymes, indicating a different mechanism of action. Taken together, CAM assay represents and invaluable model, demonstrating the PtNPs capability of repressing angiogenesis, decrease amino acid contents and disrupt the TCA cycle.
ER  -

MITREVSKA, Katerina, Miguel Angel Merlos RODRIGO, Natalia CERNEI, Hana MICHALKOVA, Zbynek SPLICHAL, David HYNEK, Ondrej ZITKA, Zbynek HEGER, Pavel KOPEL, Vojtech ADAM and Vedran MILOSAVLJEVIC. Chick chorioallantoic membrane (CAM) assay for the evaluation of the antitumor and antimetastatic activity of platinum-based drugs in association with the impact on the amino acid metabolism. \textit{Materials Today Bio}. AMSTERDAM: Elsevier, 2023, vol.~19, Apr, p.~1-14. ISSN~2590-0064. Available from: https://dx.doi.org/10.1016/j.mtbio.2023.100570.

Detailed Information on Publication Record